KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors
- Thursday, November 12, 2020, 6:53
- Business
- Add a comment
JERUSALEM, Nov. 12, 2020 /PRNewswire/ — KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced dosing of the first patient in its Phase 1/2 clinical trial (NCT04440735) assessing its lead product, DSP107, a bi-functional…
About the Author
adminasapcorp has written 41558 stories on this site.